Introduction {#sec1}
============

Age-related macular degeneration (AMD) is a retinal degenerative disease that is an important cause of blindness and central vision loss in the elderly who are over 55 years \[[@B1],[@B2]\]. The incidence rate is 13%, accounting for 20% of the causes of blindness in the elderly, especially in developed countries \[[@B3],[@B4]\]. The early stages, characterized by subretinal deposits (drusen) on the Bruch membrane and the extracellular matrix separating the choriocapillaris from the retinal pigment epithelium (RPE), affect 15.4% of those aged more than 65 years; the late stages, including abnormal blood vessels growing from the choriocapillaris through the Bruch membrane (neovascular disease or wet AMD) and the degeneration of photoreceptors and RPE cells resulting in geographic atrophy (geographic atrophy or dry AMD) \[[@B5]\]. The exact etiology of AMD has not been determined so far, which is likely to be the result of a complex cross-reflection of multiple factors, such as inheritance, age, ethnicity, family history, smoking, nutritional factors and sun exposure \[[@B1],[@B6],[@B7]\]. A genome-wide association study (GWAS) showed a clearer view about significant links between AMD risk and genetic variations in 2005, suggesting AMD is a polygenic disease \[[@B8]\], which triggered numerous studies involving the genetic associations of AMD in the following 1.5 decades \[[@B9]\].

The complement system is an important mediator of natural and acquired immunity in humans \[[@B12]\]. A dysfunctional complement pathway has been proposed to increase retinal cell damage via increased formation of drusen deposits, atrophy, and cell degeneration and progression to choroidal neovascularization (CNV) \[[@B13],[@B14]\]. So far, *component 2* (rs547154 and rs9332739) \[[@B15]\], *component 5* \[[@B16]\], *factor B* (L9H) \[[@B17]\] and *factor H* (Y402H) \[[@B18]\] polymorphisms have been observed associated with AMD susceptibility. In 2015, our team first reported the association between *component 3* gene polymorphisms and AMD risk and suggested rs2230199, rs11569536, rs1047286 and 2250656 SNPs may be related to AMD development \[[@B19]\]. Nowadays, many recent studies focused on another family member in complement system, named factor I (CFI).

CFI gene encodes a serine proteinase that is essential for regulating the complement cascade and is expressed by hepatocytes, macrophages, lymphocytes, endothelial cells and fibroblasts \[[@B20]\]. The encoded preproprotein is cleaved to produce both heavy and light chains, which are linked by disulfide bonds to form a heterodimeric glycoprotein. This heterodimer can cleave and inactivate the complement components C4b and C3b, and it prevents the assembly of the C3 and C5 convertase enzymes \[[@B21]\] (<https://www.ncbi.nlm.nih.gov/gene/3426>).

Three common polymorphisms in *CFI* gene is rs10033900 (wide allele T to mutation allele C), rs2285714 (wide allele T to mutation allele C) and rs141853578 (wide allele C to mutation allele T). Fagerness et al. first found rs1003390 SNP remained the most highly associated SNP with a *P*-value of 6.46 × 10^−8^ (OR = 0.7056 referring to lower-risk C-allele) for AMD \[[@B22]\]. Subsequently, several related articles have been published.

In view of the foregoing, we realized the vital role of *CFI* gene two common polymorphisms (rs10033900 and rs2285714) and preformed a comprehensive meta-analysis to make convincing conclusions \[[@B23]\].

Methods {#sec2}
=======

Search strategy {#sec2-1}
---------------

We searched relative studies from PubMed and Other databases (Embase, Google Scholar, Wanfang, CNKI, Web of Science) before February 8, 2020. The keywords were "age-related macular degeneration or AMD," "polymorphism or variant," and "CFI or complement factor I." With these terms, a total of 11 different articles were included from above databases based on our inclusion criteria. Stages of AMD were assigned based on the classification of the Age-Related Eye Disease Study (AREDS) \[[@B34]\].

Inclusion and exclusion criteria {#sec2-2}
--------------------------------

Included studies were according with (a) the correlation between AMD risk and *CFI* gene rs10033900 and/or rs2285714 polymorphisms; (b) case--control studies, and (c) adequate numbers of each genotypes (CC, CT, and TT) in case and control groups. Studies were excluded if they (a) included no control information; (b) didn\'t contain genotype frequency data, and (c) were duplicated studies with some other papers.

Data extraction {#sec2-3}
---------------

Two authors (Qianqian Yu and Chao Sun) independently screened all papers that according with the selection criteria. These data included the first author's last name, publication year, country of origin, ethnicity, Hardy--Weinberg equilibrium (HWE) of control group, genotyping method and AMD disease types (neovascular disease and geographic atrophy in AMD). Ethnicity was categorized as Caucasian or Asian. The control subgroups were classified to population-based (PB) and hospital-based (HB).

Statistical analysis {#sec2-4}
--------------------

Based on the genotype frequencies for cases and controls, odds ratios (OR) with 95% confidence intervals (CI) were used to measure the strengths of associations. The statistical significance of the OR was determined with the *Z* test \[[@B35]\]. The heterogeneity assumption among studies was evaluated using a *χ*^2^-square-based *Q* test. If *P*-value \> 0.10 for the *Q* test was indicated, a lack of heterogeneity among studies, other words, Mantel--Haenszel (fixed-effects model) was chosen, otherwise, the DerSimonian-Laird (random-effects model) was applied \[[@B36],[@B37]\]. We investigated the correlation between rs10033900 and/or rs2285714 polymorphisms and AMD risk by testing whole five genetic models: A versus G, AG versus GG, AA + AG versus GG, AA versus GG and AA versus AG+GG. A sensitivity analysis was performed by omitting studies, one after another, to assess the stability of results. The departure of frequencies of the rs11200638 polymorphism from expectation under HWE was assessed by the Pearson's *χ*^2^ test, *P* \< 0.05 was considered significant \[[@B38]\]. The funnel plot was evaluated by Begg's test, and the publication bias was evaluated by Egger's test, whose *P*-value \< 0.05 was considered significant \[[@B39]\]. All statistical tests for this meta-analysis were performed using version 10.0 Stata software (StataCorp LP, College Station, TX, U.S.A.). The power and sample size analysis of our meta-analysis was calculated by a program called PS: Power and Sample Size Calculation (<http://biostat.mc.vanderbilt.edu/wiki/Main/PowerSampleSize#Windows>).

Network of gene-interaction of CFI gene {#sec2-5}
---------------------------------------

To more complete understanding of the role of CFI in AMD, the network of gene-gene interactions for CFI gene was utilized through String online server (<http://string-db.org/>) \[[@B40]\].

Results {#sec3}
=======

Study searching and their basic information {#sec3-1}
-------------------------------------------

Using various combinations of key terms, a total of 632 article titles were garnered by a document search using the PubMed (385 titles) and other databases (247 titles). As shown in [Figure 1](#F1){ref-type="fig"}, 423 articles were excluded after screening the "Abstract" sections of the manuscripts. The full texts were then evaluated, and 198 additional articles were excluded due to duplication (154), meta-analysis or systematic analysis (28), only case group (4), and no data for each genotype (12). Finally, 11 different articles \[[@B23]\] were included in our meta-analysis, including 12 case--control studies about *CFI* gene rs10033900 polymorphism and total AMD risk and 3 case--control studies about rs2285714 polymorphism and AMD risk. The available clinical information in all publications were shown in Supplementary Table S1. Eleven case--control studies were involved to neovascular disease and geographic atrophy. All case--control studies about rs10033900 polymorphism were consistent with HWE in control groups ([Table 1](#T1){ref-type="table"}). In addition, we checked the minor allele frequency (MAF) reported for the six main worldwide populations in the 1000 Genomes Browser (<https://www.ncbi.nlm.nih.gov/snp/rs10033900>): Global (0.495), Europe (0.537), East Asian (0.388), South Asian (0.31), African (0.660), American (0.53) (<https://www.ncbi.nlm.nih.gov/snp/rs2285714>); Global (0.252), Europe (0.393), East Asian (0.202), South Asian (0.39), African (0.023), American (0.37) ([Figure 2](#F2){ref-type="fig"}A,B). Finally, we calculated the C-allele frequency both in Asians and Caucasians in case and control groups, which suggested C-allele in Caucasians had higher frequency than Asians in both case and control groups ([Figure 3](#F3){ref-type="fig"}). The genotyping methods included polymerase chain reaction-restrictive fragment length polymorphism and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry, sequencing, mixed methods, and TaqMan.

![Flow chart illustrating the search strategy used to identify association studies for *CFI* gene two polymorphisms and AMD risk](bsr-40-bsr20200406-g1){#F1}

![The MAF reported for the six main worldwide populations in the 1000 Genomes Browser\
The MAF of minor-allele (mutant-allele) for *CFI* gene rs10033900 (**A**) and rs2285714 (**B**) polymorphism from the 1000 Genomes online database and present analysis.](bsr-40-bsr20200406-g2){#F2}

![C-allele frequencies for the *CFI* gene rs10033900 polymorphism among cases/controls stratified by ethnicity](bsr-40-bsr20200406-g3){#F3}

###### Characteristics of included studies in *CFI* polymorphisms and AMD risk

  Author        Year   Country           Ethnicity   Type                  Case   Control   SOC   Cases   Controls   HWE   Genotype                         
  ------------- ------ ----------------- ----------- --------------------- ------ --------- ----- ------- ---------- ----- ---------- ----- ----- --------- ---------------
  rs1003900                                                                                                                                                 
  Total                                                                                                                                                     
  Yang          2014   China             Asian       Neovascular disease   300    299       HB    32      141        127   35         138   126   0.764     MALDI-TOF MS
  Seddon        2010   U.S.A.            Caucasian   Advanced AMD          545    275       PB    120     278        147   87         134   54    0.852     MALDI-TOF MS
  Reynolds      2009   U.S.A.            Caucasian   Advanced AMD          102    55        PB    29      50         23    20         28    7     0.561     MALDI-TOF MS
  Cipriani      2012   U.K.              Caucasian   Advanced AMD          804    410       PB    186     407        211   101        207   102   0.843     Mixed methods
  Cipriani      2012   U.K.              Caucasian   Advanced AMD          222    334       PB    45      130        47    80         177   77    0.273     Mixed methods
  Wu            2013   China             Asian       AMD                   235    140       HB    13      68         154   12         58    70    0.997     PCR-RFLP
  Smailhodzic   2012   The Netherlands   Caucasian   Neovascular disease   192    144       HB    48      92         52    29         80    35    0.175     Sequencing
  Aygun         2019   Turkey            Caucasian   Advanced AMD          109    92        HB    26      54         29    24         39    29    0.151     Sequencing
  Qian          2014   China             Asian       AMD                   288    384       HB    48      127        113   48         152   184   0.063     TaqMan
  Kondo         2010   U.S.A.            Caucasian   Neovascular disease   116    189       HB    6       59         51    31         85    73    0.459     TaqMan
  Peter         2011   U.S.A.            Caucasian   AMD                   146    1260      PB    34      68         44    348        623   289   0.751     TaqMan
  Yu            2011   U.S.A.            Caucasian   Advanced AMD          1072   216       PB    243     521        308   65         107   44    0.998     TaqMan
  AMD type                                                                                                                                                  
  Seddon        2010   U.S.A.            Caucasian   Geographic atrophy    139    275       PB    26      72         41    87         134   54    0.852     MALDI-TOF MS
  Reynolds      2009   U.S.A.            Caucasian   Geographic atrophy    53     55        PB    19      20         14    20         28    7     0.561     MALDI-TOF MS
  Seddon        2010   U.S.A.            Caucasian   Neovascular disease   406    275       PB    94      206        106   87         134   54    0.852     MALDI-TOF MS
  Reynolds      2009   U.S.A.            Caucasian   Neovascular disease   49     55        PB    10      30         9     20         28    7     0.561     MALDI-TOF MS
  Yang          2014   China             Asian       Neovascular disease   300    299       HB    32      141        127   35         138   126   0.764     MALDI-TOF MS
  Aygun         2019   Turkey            Caucasian   Geographic atrophy    46     92        HB    12      24         10    24         39    29    0.151     Sequencing
  Smailhodzic   2012   The Netherlands   Caucasian   Neovascular disease   192    144       HB    48      92         52    29         80    35    0.175     Sequencing
  Aygun         2019   Turkey            Caucasian   Neovascular disease   63     92        HB    14      30         19    24         39    29    0.151     Sequencing
  Yu            2011   U.S.A.            Caucasian   Geographic atrophy    258    216       PB    56      121        81    65         107   44    0.998     TaqMan
  Kondo         2010   U.S.A.            Caucasian   Neovascular disease   116    189       HB    6       59         51    31         85    73    0.459     TaqMan
  Yu            2011   U.S.A.            Caucasian   Neovascular disease   814    216       PB    187     400        227   65         107   44    0.998     TaqMan
  rs2285714                                                                                                                                                 
  Aygun         2019   Turkey            Caucasian   AMD                   111    96        HB    42      56         13    32         47    17    0.971     Sequencing
  Wu            2013   China             Asian       AMD                   239    140       HB    124     111        4     68         71    1     \<0.001   PCR-RFLP
  Yang          2014   China             Asian       AMD                   300    299       HB    188     92         20    167        121   11    0.052     MALDI-TOF MS

Abbreviations: HB, hospital-based; HWE, Hardy--Weinberg equilibrium of control group; MALDI-TOF MS, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry; PB, population-based; PCR-RFLP, polymerase chain reaction followed by restriction fragment length polymorphism; SOC, source of control;.

Quantitative synthesis {#sec3-2}
----------------------

### Rs10033900 polymorphism {#sec3-2-1}

In whole analysis, decreased associations were observed in three genetic models (C-allele vs. T-allele: OR: 0.87, 95% CI: 0.76--0.99, *P* = 0.001 for heterogeneity, [Figure 4](#F4){ref-type="fig"}A, *P* = 0.029; CC vs. TT: OR: 0.75, 95% CI: 0.58--0.97, *P* = 0.003 for heterogeneity, *P* = 0.025; CC vs. CT+TT: OR: 0.82, 95% CI: 0.68--0.98, *P* = 0.039 for heterogeneity, *P* = 0.028). In subgroup analysis by ethnicity, based on different frequency of races, there had decreased associations between this polymorphism and AMD in Caucasians not Asians in all models (C-allele vs. T-allele: OR = 0.84, 95% CI = 0.77--0.91, *P*~heterogeneity~ = 0.125, *P* \< 0.001, [Figure 4](#F4){ref-type="fig"}B, CT vs. TT: OR = 0.87, 95% CI = 0.75--1.00, *P*~heterogeneity~ = 0.380, *P* = 0.047, CC+CT vs. TT: OR = 0.81, 95% CI = 0.70--0.92, *P*~heterogeneity~ = 0.246, *P* = 0.002, CC vs. TT: OR = 0.69, 95% CI = 0.54--0.88, *P*~heterogeneity~ = 0.060, *P* = 0.003; CC vs. CT+TT:OR = 0.77, 95% CI = 0.64--0.93, *P*~heterogeneity~ = 0.098, *P* = 0.007). In addition, regular analysis by source of control, also significantly trend were found for this SNP in PB rather than HB studies (C-allele vs. T-allele: OR = 0.82, 95% CI = 0.75--0.90, *P*~heterogeneity~ = 0.153, *P* \< 0.001, CT vs. TT: OR = 0.84, 95% CI = 0.71--0.98, *P*~heterogeneity~ = 0.308, *P* = 0.031, [Figure 5](#F5){ref-type="fig"}, CC+CT vs. TT: OR = 0.78, 95% CI = 0.67--0.91, *P*~heterogeneity~ = 0.159, *P* = 0.001, CC vs. TT: OR = 0.67, 95% CI = 0.56--0.81, *P*~heterogeneity~ = 0.173, *P* \< 0.001; CC vs. CT+TT:OR = 0.76, 95% CI = 0.65--0.88, *P*~heterogeneity~ = 0.519, *P* \< 0.001) ([Table 2](#T2){ref-type="table"}) ([Figure 5](#F5){ref-type="fig"}). AMD have different types and stages, the difference of clinical presentation for dry and wet AMD is completely different, so we firmly believed that the correlations existed should be evaluated separately, significant negative associations were found both for geographic atrophy (such as C-allele vs. T-allele: OR = 0.72, 95% CI = 0.60--0.85, *P*~heterogeneity~ = 0.158, *P* \< 0.001, CC vs. TT: OR = 0.51, 95% CI = 0.36--0.72, *P*~heterogeneity~ = 0.168, *P* \< 0.001, [Figure 6](#F6){ref-type="fig"}) and neovascular disease (for example in C-allele vs. T-allele: OR = 0.82, 95% CI = 0.74--0.91, *P*~heterogeneity~ = 0.237, *P* \< 0.001, CC vs. TT: OR = 0.64, 95% CI = 0.51--0.80, *P*~heterogeneity~ = 0.142, *P* \< 0.001, [Figure 6](#F6){ref-type="fig"}). Finally, different genotype methods were applied in included studies, we tried to in each method, whether associations may exist in our analysis, we found some positive results in MALDI-TOF-MS (CC vs. CT+TT: OR = 0.69, 95% CI = 0.53--0.89, *P*~heterogeneity~ = 0.449, *P* = 0.004) ([Figure 7](#F7){ref-type="fig"}) ([Table 3](#T3){ref-type="table"}).

![Forest plot of AMD risk associated with *CFI* gene rs10033900 polymorphism (C-allele vs. T-allele) by ethnicity subgroup\
(**A**) Random effect model and (**B**) fixed effect model. The squares and horizontal lines correspond to the study-specific OR and 95% CI. The area of the squares reflects the weight (inverse of the variance). The diamond represents the summary OR and 95% CI.](bsr-40-bsr20200406-g4){#F4}

![Forest plot of AMD risk associated with *CFI* gene rs10033900 polymorphism (CT vs. TT) by source of control subgroup](bsr-40-bsr20200406-g5){#F5}

![Forest plot of AMD risk associated with *CFI* gene rs10033900 polymorphism (CC vs. TT) by AMD type subgroup](bsr-40-bsr20200406-g6){#F6}

![Forest plot of AMD risk associated with *CFI* gene rs10033900 polymorphism (CC vs. CT+TT) by genotyping methods subgroup](bsr-40-bsr20200406-g7){#F7}

###### Results of the meta-analysis on *CFI* polymorphisms and AMD risk in total and types of subgroups

  Variables             *N*   Case/       C-allele vs. T-allele   CT vs. TT   CC+CT vs. TT   CC vs. TT           CC vs. CT+TT                                                                                                                
  --------------------- ----- ----------- ----------------------- ----------- -------------- ------------------- -------------- ------- ------------------- ------- ------- ------------------- -------- ------- ------------------- ------- -------
  rs1003900                                                                                                                                                                                                                                  
  Total                 12    4131/3798   0.87 (0.76--0.99)       0.001       0.029          0.89 (0.75--1.05)   0.040          0.177   0.85 (0.70--1.02)   0.004   0.073   0.75 (0.58--0.97)   0.003    0.025   0.82 (0.68--0.98)   0.039   0.028
  Ethnicity                                                                                                                                                                                                                                  
  Asian                 3     823/823     0.94 (0.62--1.41)       0.001       0.751          0.92 (0.58--1.52)   0.004          0.747   0.92 (0.54--1.57)   0.001   0.764   0.97 (0.51--1.82)   0.033    0.916   1.07 (0.79--1.45)   0.165   0.681
  Caucasian             9     3308/2975   0.84 (0.77--0.91)       0.125       0.000          0.87 (0.75--1.00)   0.380          0.047   0.81 (0.70--0.92)   0.246   0.002   0.69 (0.54--0.88)   0.060    0.003   0.77 (0.64--0.93)   0.098   0.007
  SOC                                                                                                                                                                                                                                        
  HB                    6     1240/1248   0.93 (0.74--1.18)       0.002       0.549          0.96 (0.72--1.28)   0.027          0.781   0.94 (0.69--1.27)   0.009   0.668   0.86 (0.55--1.37)   0.013    0.532   0.89 (0.60--1.31)   0.026   0.548
  PB                    6     2891/2550   0.82 (0.75--0.90)       0.153       0.000          0.84 (0.71--0.98)   0.306          0.031   0.78 (0.67--0.91)   0.159   0.001   0.67 (0.56--0.81)   0.173    0.000   0.76 (0.65--0.88)   0.519   0.000
  AMD type--                                                                                                                                                                                                                                 
  Neovascular disease   7     1940/1270   0.82 (0.74--0.91)       0.237       0.000          0.87 (0.73--1.04)   0.808          0.119   0.80 (0.68--0.95)   0.647   0.010   0.64 (0.51--0.80)   0.142)   0.000   0.72 (0.54--0.96)   0.068   0.024
  Geographic atrophy    4     496/638     0.72 (0.60--0.85)       0.158       0.000          0.70 (0.52--0.95)   0.103          0.020   0.66 (0.42--1.04)   0.094   0.075   0.51 (0.36--0.72)   0.168)   0.000   0.66 (0.50--0.86)   0.355   0.003
  Genotyping                                                                                                                                                                                                                                 
  Sequencing            2     301/236     1.05 (0.82--1.33)       0.962       0.707          0.97 (0.64--1.45)   0.176          0.876   1.01 (0.69--1.48)   0.339   0.974   1.10 (0.68--1.79)   0.956)   0.696   1.13 (0.75--1.69)   0.345   0.555
  TaqMan                4     1622/2049   0.86 (0.63--1.17)       0.000       0.338          0.91 (0.65--1.28)   0.030          0.598   0.85 (0.57--1.27)   0.003   0.430   0.67 (0.35--1.28)   0.000)   0.223   0.75 (0.47--1.21)   0.006   0.239
  MALDI-TOF MS          3     947/629     0.80 (0.69--0.93)       0.124       0.003          0.86 (0.68--1.10)   0.338          0.224   0.79 (0.63--1.00)   0.149   0.048   0.61 (0.45--0.83)   0.199)   0.002   0.69 (0.53--0.89)   0.449   0.004
  Mixed methods         2     1026/744    0.95 (0.83--1.09)       0.886       0.474          1.02 (0.81--1.30)   0.371          0.846   0.98 (0.78--1.23)   0.472   0.890   0.90 (0.68--1.19)   0.912)   0.463   0.88 (0.70--1.11)   0.604   0.290
  rs2285714                                                                                                                                                                                                                                  
  Total                 3     650/535     1.13 (0.94--1.36)       0.833       0.210          0.72 (0.25--2.02)   0.063          0.527   0.86 (0.52--1.43)   0.107   0.564   0.92 (0.54--1.57)   0.178)   0.748   1.25 (0.99--1.58)   0.854   0.065

*P*~h~: value of *Q*-test for heterogeneity test; *P*: *Z*-test for the statistical significance of the OR

###### Publication bias tests (Begg's funnel plot and Egger's test for publication bias test) for *CFI* rs1003900 and rs2285714 polymorphism

  Egger's test            Begg's test                                                      
  ----------------------- ------------- ------- ------- ------- ------------------- ------ -------
  **rs1003900**                                                                            
  C-allele vs. T-allele   -2.336        2.042   −0.77   0.46    (−9.116--4.444)     0.62   0.537
  CT vs. TT               -1.799        2.063   −0.87   0.404   (−6.396--2.798)     0.89   0.373
  CC+CT vs. TT            -1.997        2.15    −0.93   0.375   (−6.788--2.793)     0.89   0.373
  CC vs. TT               -0.994        1.16    −0.86   0.412   (−3.578--1.591)     0.48   0.631
  CC vs. CT+TT            -0.577        1.243   −0.46   0.653   (−3.347--2.194)     0.62   0.537
  **rs2285714**                                                                            
  C-allele vs. T-allele   1.247         1.837   0.68    0.62    (−22.094--24.587)   0.52   0.602
  CT vs. TT               -0.122        0.318   −0.38   0.767   (−4.168--3.923)     0.52   0.602
  CC+CT vs. TT            -0.124        0.323   −0.38   0.766   (−4.234--3.985)     0.52   0.602
  CC vs. TT               -0.092        0.321   −0.29   0.823   (−4.177--3.992)     0.52   0.602
  CC vs. CT+TT            0.749         0.89    0.84    0.555   (−10.56--12.059)    0.52   0.602

### Rs2285714 polymorphism {#sec3-2-2}

Given the limited case--control studies about this SNP, subgroups could not be analyzed separately. No association was detected in the whole data (data not shown) ([Table 2](#T2){ref-type="table"}).

Bias diagnosis for publication and sensitivity analysis {#sec3-3}
-------------------------------------------------------

The publication bias was evaluated by both Begg's funnel plot and Egger's test. At beginning, the shape of the funnel plots seemed asymmetrical in allele comparison for rs10033900 and rs2285714 by Begg's test, suggesting no publication bias was existed. Then, Egger's test was applied to provide statistical evidence of funnel plot symmetry. As a result, no obvious evidence of publication bias was observed (such as C-allele vs. T-allele, *t* = −0.77, *P* = 0.46 for Egger's test; *z* = 0.62, *P* = 0.537 for Begg's test, [Figure 8](#F8){ref-type="fig"}A,B for rs10033900; C-allele vs. T-allele, *t* = 0.68, *P* = 0.62 for Egger's test; *z* = 0.52, *P* = 0.602 for Begg's test, [Figure 8](#F8){ref-type="fig"}C,D for rs2285714) ([Table 3](#T3){ref-type="table"}).

![The publication bias for CFI gene polymorphisms\
Begg's funnel plot for publication bias test (C-allele vs. T-allele) (**A** for rs10033900; **C** for rs2285714). Each point represents a separate study for the indicated association. Log \[OR\], natural logarithm of OR. Horizontal line, mean effect size. Egger's publication bias plot (C-allele vs. T-allele) (**B** for rs10033900; **D** for rs2285714).](bsr-40-bsr20200406-g8){#F8}

To delete studies that may influence the power and stability of whole study, we applied the sensitive analysis, finally, no sensitive case--control studies were found for two SNPs ([Figure 9](#F9){ref-type="fig"}A,B).

![Sensitivity analysis for CFI gene polymorphisms\
Sensitivity analysis between CFI gene polymorphisms and AMD risk (C-allele vs. T-allele) (**A** for rs10033900; **B** for rs2285714).](bsr-40-bsr20200406-g9){#F9}

Gene--gene network diagram and interaction of online website {#sec3-4}
------------------------------------------------------------

String online server indicated that CFI gene interacts with numerous genes. The network of gene--gene interaction has been illustrated in [Figure 10](#F10){ref-type="fig"}.

![Human CFI interactions network with other genes obtained from String server\
At least 10 genes have been indicated to correlate with HTRA1 gene. CFH: complement factor H; C3: complement C3; CFB: complement factor B; CD46: membrane cofactor protein; CFHR3: complement factor H-related protein 3; C4B: complement C4-B; C4A: complement C4-A; C2: complement C2; C4BPA: C4b-binding protein alpha chain; CR1: complement receptor type 1.](bsr-40-bsr20200406-g10){#F10}

Discussion {#sec4}
==========

Because of the critical consequences about the visual loss caused by AMD, especially advanced AMD (atrophic/dry or neovascular/wet), it is necessary to study its etiology and mechanism, then to development early diagnostic methods and effective treatments. Nowadays, vascular endothelial growth factor (VEGF) inhibitors are widely recognized as effective drugs in clinical application for CNV (wet AMD) \[[@B41]\]. It is well known that VEGF is involved in wet AMD development because that the formation of angiogenesis and vascular permeability can lead to fluid leakage across the blood vessels, and visual loss in the final \[[@B44]\]. Anti-VEGF agents such as ranibizumab and bevacizumab have been widely applied in the clinic \[[@B45],[@B46]\], in addition, have been proved to effectively slow the progress of CNV; however, heterogeneity was observed among patients in terms of the invalid samples and who have shorter duration of treatment \[[@B47]\]. It was hypothesized that genetic factors may participate in this period of this heterogeneous response, such as the variants of complement system genes. In addition, in the mechanism of dry AMD formation, inflammation and complement-mediated attack is existed in RPE, Bruch's membrane and choroid region, which involves the complement cascade pathway. Increasing evidence has shown that inflammatory processes, especially the complement activation pathway, may play a major role in the pathogenesis of AMD \[[@B48],[@B49]\]. Thus, we can regulate complement and inflammatory system to delay the development of dry AMD \[[@B50],[@B51]\].

Next, to identify some novel detection markers and target drugs for different types of AMD is the current and future research focus on the direction. In the introduction section, we have enunciated the genetic factors may help us search potential high-risk group about AMD, which can be prevented and treated in advance. CFB, C2, C3, CFH in complement system has been widely reported. Another molecular CFI remains equivocal. Yang et al. made a meta-analysis that rs10033900 and rs2285714 SNPs had significant associations with AMD risk \[[@B32]\], whose report was indelicate that subgroups was not analyzed. An additional article in 2019 has been published, so we performed an updated meta-analysis to come to a more convincing conclusion about *CFI* gene polymorphisms and AMD susceptibility.

The best part of our analysis is that decreased associations were found about rs10033900 SNP and AMD risk in Caucasians, positive correlations were also observed both in geographic atrophy and neovascular disease subtype. In other words, if individuals carry on CC genotype or C-allele from peripheral blood test, which may indicate that it is possible to have a lower incidence of AMD, on the contrary, individuals carrying T-allele or TT genotype may have a high susceptibility for AMD. Therefore, it should offer us some preventions to intervene, or carry out treatments as soon as possible. To sum up, we wish to use this method to reduce the incidence of AMD and improve the cure rate of early treatment. In addition, the power of present study was 0.76, which suggested our conclusions were relative stable and convincing, which should be included more clinical information to confirm.

In addition, in order to identify the network correlation of CFI, the online analysis system-String was applied to predict potential and functional partners related to CFI, which can help us to better understand the value for detection and concern. Finally, ten genes were predicted. Among them, the scores are general high, and eight genes are members in complement system. In addition, researchers have focused on the complement pathways involved in AMD and their preventive/personalized medicine correspondingly \[[@B52],[@B53]\].

The associations among AMD development and these genes majority involves gene polymorphisms. The highest score of association was CFH (0.999), Harrison et al. suggested the decreased heparin-binding affinity caused by the Y402H polymorphism (a common SNP in CFH gene) may recognize of SCR7^H402^, which may contribute to the pathogenesis of AMD \[[@B54]\]. C3 gene contains many SNPs, our previous meta and Zhang et al. both detected some increased and decreased SNPs in AMD \[[@B19],[@B55]\]. Wang et al. performed a systematic analysis and suggested rs641153 in the CFB gene was a protective factor in advanced AMD both in Caucasians and Asians \[[@B17]\]. Rs547154 and rs9332739 SNPs had both decreased correlations to AMD risk \[[@B15]\]. In a word, we should deep explore these partners of CFI gene, and gene--gene interactions in the development of AMD in the next step.

There are some inherent limitations of our study should be declared. First, further studies should focus on Mixed and African populations, which was vacant in present analysis and need many more studies to consider rs2285714 SNP. Second, gene--gene and gene--environment interactions were not well analyzed. It is possible that specific environmental and lifestyle factors alter the associations between *CFI* polymorphisms and AMD, including age, diabetes, smoking, familial history and hypertension. Third, whether the AMD patients have other complications, such as kidney disease, heart disease, all the included paper have not been reported. Further comprehensive studies should include above information, which may influence the function of *CFI* gene polymorphisms. Fourth, vision is the most concerned-clinical indicator of AMD, future studies should include the value of the vision and analyze the relationships between *CFI* polymorphisms and the degree of visual impairment, which may help us better detect disease progression.

In conclusion, our present meta-analysis suggests that *CFI* rs10033900 polymorphism may be powerful associated with AMD risk, which may be as a clinical biomarker for detection in the future.

Supplementary Material
======================

###### Supplementary Table S1

###### 

Click here for additional data file.

Competing Interests {#sec5}
===================

The authors declare that there are no competing interests associated with the manuscript.

Funding {#sec6}
=======

This study was supported by grants from the National Natural Science Foundation of China \[grant number 81770941\].

Author Contribution {#sec7}
===================

Q.Y. conceived the study. C.S. searched the databases and extracted the data. J.Z. analyzed the data. Q.Y. wrote the draft of the paper. Y.Y. reviewed the manuscript.

AMD
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